1-(2-氟苯基)乙胺 | 74788-44-6

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2-氟苯基)乙胺
• 英文名称: 1-(2-Fluorophenyl)ethylamine
• 英文别名: 1-(2-fluorophenyl)ethanamine
• CAS: 74788-44-6
• 化学式: C₈H₁₀FN
• mdl: MFCD04038307
• 分子量: 139.173
• InChiKey: DIWHJJUFVGEXGS-UHFFFAOYSA-N

物化性质

• 沸点：
  70.4-73.5°C
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R34
• 危险品运输编号：
  UN 2735
• 海关编码：
  2921499090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(2-Fluorophenyl)ethylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H412: Harmful to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(2-Fluorophenyl)ethylamine
CAS number: 74788-44-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H10FN
Molecular weight: 139.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-氟苯基)乙胺 在 水 、 hydroxide 作用下， 生成 (S)-1-(2-氟苯基)乙胺
  参考文献：
  名称：

  Enantiomerically pure amines by a new method: biotransformation of oxalamic esters using the lipase from Candida antarctica

  摘要：

  1-苯乙胺及其取代的1-苯乙胺的辛基草酰胺酯在南极酵母（Candida antarctica）来源的脂肪酶B的催化下以高立体选择性进行动力学分解。

  DOI：

  10.1039/cc9960002415
• 作为产物：
  描述：

  2'-氟苯乙酮 在 ammonium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 1-(2-氟苯基)乙胺
  参考文献：
  名称：

  基于（+）-（18-冠-6）-2,3,11,12-四羧酸的手性固定相上苯二胺及其类似物的液相色谱拆分。

  摘要：

  芬迪林是一种有效的抗心绞痛治疗冠心病的药物，其十六种类似物在基于（+）-（18-crown-6）-2,3,11,12-四羧酸的CSP上拆分。当流动相由比例为80/20 / 0.1 / 0.5（v / v）的甲醇-乙腈-三氟乙酸-三乙胺组成的流动相时，芬迪林的分离度（α）为1.25，分离度（RS）为1.55 / v / v）。色谱分析法比较了芬迪林及其类似物的拆分行为，表明与芬迪林仲氨基键合的3,3-二苯丙基在手性识别中很重要，而苯基与苯丙氨酸之间的空间体积差异也很重要。芬迪林手性中心的甲基在手性识别中也很重要。

  DOI：

  10.3390/molecules191221386

文献信息

• Primary Amines by Transfer Hydrogenative Reductive Amination of Ketones by Using Cyclometalated Ir^IIICatalysts
  作者：Dinesh Talwar、Noemí Poyatos Salguero、Craig M. Robertson、Jianliang Xiao

  DOI：10.1002/chem.201303541

  日期：2014.1.3

  Cyclometalated iridium complexes are found to be versatile catalysts for the direct reductive amination (DRA) of carbonyls to give primary amines under transfer‐hydrogenation conditions with ammonium formate as both the nitrogen and hydrogen source. These complexes are easy to synthesise and their ligands can be easily tuned. The activity and chemoselectivity of the catalyst towards primary amines

  已发现环金属化铱配合物是通用的催化剂，用于羰基的直接还原胺化（DRA），在转移加氢条件下以甲酸铵作为氮源和氢源生成伯胺。这些复合物易于合成，其配体易于调节。催化剂对伯胺的活性和化学选择性极好，底物与催化剂之比（S / C）为1000是可行的。芳族和脂族伯胺均以高收率获得。此外，对于β-酮醚已经实现了均相催化的转移加氢DRA的第一个实例，从而产生了相应的β-氨基醚。此外，通过这种方法还可以以极高的收率获得非天然α-氨基酸。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：US20200247815A1

  公开（公告）日：2020-08-06

  The present invention relates to pyrazolyl-containing tricyclic derivative, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protease such as ERK (MAPK) inhibitor in the treatment of cancers, bone diseases, inflammatory diseases, immunological diseases, nervous system diseases, metabolic diseases, respiratory diseases and heart diseases, wherein the definition of each substituent in the general formula (1) is the same as defined in the description.

  本发明涉及吡唑基含有的三环衍生物，其制备方法及其用途。具体而言，本发明涉及一种如通式(I)所示的化合物，其制备方法及含有该化合物的药物组合物，以及将其用作蛋白酶，如ERK（MAPK）抑制剂，用于治疗癌症、骨疾病、炎症性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸系统疾病和心脏疾病，其中通式（1）中每个取代基的定义与描述中定义的相同。
• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• Rh(III)-catalyzed synthesis of isoquinolines using the N-Cl bond of N-chloroimines as an internal oxidant
  作者：Bing Qi、Lili Fang、Qi Wang、Shan Guo、Pengfei Shi、Benfa Chu、Jin Zhu

  DOI：10.1016/j.tetlet.2020.151771

  日期：2020.4

  The Rh(III)-catalyzed coupling of N-chloroimines with alkynes for the efficient synthesis of isoquinolines is reported. This represents the first use of the N-Cl bond of N-chloroimines as an internal oxidant for construction of the isoquinoline skeleton. The synthesis features atom and step economy, a green solvent (EtOH), mild reaction conditions, and a broad substrate scope.2020 Elsevier Ltd. All

  报道了Rh（III）催化的N-氯亚胺与炔烃的偶联，用于有效合成异喹啉。这表示在第一次使用的N-Cl键的Ñ -chloroimines作为用于构建异喹啉骨架的内部氧化剂。该合成具有原子和步骤经济性，绿色溶剂（EtOH），温和的反应条件和广泛的底物范围。2020Elsevier Ltd.保留所有权利